Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Drug Discovery
- Disease
- Delivery
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 367345
– an exclusive sublicense, with rights to sublicense, under the Licensor Technology to use the Licensor Technology to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory; and
– an exclusive sublicense, with rights to sublicense, under all rights granted to License pursuant to a Joint Development and Manufacturing/Supply Agreement between Licensor and a Japanese company, to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory.
Licensor has an exclusive worldwide license, except Japan, to market and distribute the oral formulation of the product by a Japanese Party. The Japanese Party IFN means the cell culture derived human lymphoblastoid IFN.
Product means a formulation or composition containing the Japanese Party IFN and designated, detailed, or labeled for oral use in the treatment of the Licensed Indications.
Product means oral interferon-alpha lozenges for chronic hepatitis C virus infection.
IPSCIO Record ID: 274841
— an exclusive sublicense, with rights to sublicense, under the Licensor Technology to use the Licensor Technology to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory; and
— an exclusive sublicense, with rights to sublicense, under all rights granted to License pursuant to another Party License agreement to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory.
Product means a formulation or composition containing IFN and designated, detailed, or labeled for oral use in the treatment of the Licensed Indications.
Interferons (IFNs) are a group of signaling proteins made and released by host cells in response to the presence of several viruses. In a typical scenario, a virus-infected cell will release interferons causing nearby cells to heighten their anti-viral defenses.
Competing Product means a product for human use that contains IFN and is marketed, distributed or sold in the Territory that is likely to be confused with or used as a substitute for the Product, such confusion and likelihood of substitution being determined based on an analysis of factors such as, but not limited to, recommended dosage, similarity in indications for which it is marketed, distributed or sold, or similarity in tradedress or trademarks used in the marketing, distribution or sale thereof.
Parties are working together to bring a promising new prevention and treatment option for influenza to the developing world.
IPSCIO Record ID: 367573
– an exclusive sublicense, with rights to sublicense, under the Licensor Technology to use the Licensor Technology to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory; and
– an exclusive sublicense, with rights to sublicense, under all rights granted to Licensor pursuant to an Agreement between Licensor and a Party of Japan, to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory.
Licensor has an exclusive worldwide license, except Japan, to market and distribute the oral formulation of IFN by the Agreement between the Licensor and Party of Japan.
Licensor owns certain proprietary information, intellectual property, Patents and Licensor Know How, and other rights relating to the use of low dose oral IFN for the treatment or prevention of human diseases; capable of providing clinical benefit in humans 150-500 ill/Lozenge.
Bulk IFN means concentrated powdered, frozen, lyophilized or liquid HBL IFN, which can be used to Manufacture Product.
IFN developed with the Party of Japan means the cell culture derived human lymphoblastoid IFN.
IFN means human interferon alpha.
Intalfa means recombinant interferon alfa 2b produced by Licensee.
Licensee plans to launch a double-blind, placebo-controlled Phase 3 clinical trial of Licensor's orally administered interferon-alpha lozenges in India by the end of March. The study will include up to 520 patients with clinical signs and symptoms of influenza.
IPSCIO Record ID: 248341
(a) an exclusive sublicense, with rights to sublicense, under the Licensor Technology to use the Licensor Technology to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory; and
(b) an exclusive sublicense, with rights to sublicense, under all rights granted to Licensor pursuant to the HBL Agreement to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory.
IFN means human interferon alpha. HBL IFN means the cell culture derived human lymphoblastoid IFN produced by HBL.
Licensor Technology means the Licensor Patent Rights and the Licensor Know-How.
Licensor Patent Rights means all Patent Rights that are under the Control of Licensor as of the Effective Date under US patent laws’ protection, and at any time during the term that are necessary or useful to the use, development, Manufacture, marketing, promotion, distribution, sale and/or commercialization of the Product for use in the treatment of the Licensed Indications, and Improvements thereto developed by or on behalf of Licensor during the term.
IPSCIO Record ID: 248386
(a) an exclusive sublicense, with rights to sublicense, under the Licensor Technology to use the Licensor Technology to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory; and
(b) an exclusive sublicense, with rights to sublicense, under all rights granted to Licensor pursuant to the HBL Agreement to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory.
IFN means human interferon alpha.
Licensed Indications means influenza and one other human indication treated or treatable by the oral administration of IFN.
Licensor Technology means the Licensor Patent Rights and the Licensor Know-How. Licensor Patent Rights means all Patent Rights that are under the Control of Licensor as of the Effective Date and at any time during the Term that are necessary or useful to the use, development, Manufacture, marketing, promotion, distribution, sale and/or commercialization of the Product for use in the treatment of the Licensed Indication, and Improvements thereto developed by or on behalf of Licensor during the Term.
IPSCIO Record ID: 329658
The technology involves the formation of biphasic lipid vesicles for use as a vehicle for administration of a biologically active material (BiPhasixâ„¢ Technology). The BiPhasixâ„¢ Technology is a novel encapsulation and delivery platform technology.
